Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category. Insulet faces significant business and financial risks ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Morgan Stanley raised the firm’s price target on Insulet (PODD) to $325 from $317 and keeps an Overweight rating on the shares following a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

周五，Stifel分析师将Insulet Corporation（NASDAQ:PODD）的目标股价从此前的245美元上调至293美元，同时维持对该股票的持有评级。根据InvestingPro数据显示，该股目前接近其52周高点289.46美元，过去六个月内取得了55.16%的显著回报。该公司保持着强劲的财务状况，流动比率高达3.58。分析师Matthew ...

周五，BTIG分析师将Insulet Corporation（NASDAQ:PODD）的目标股价从此前的310美元上调至310美元，同时维持对该股的买入评级。这家市值达202.4亿美元的医疗设备公司在过去六个月内股价回报率达55%，展现出显著增长势头。根据 InvestingPro ...